Can a respiratory #virus infection confer #immunity against the other #respiratory virus? A much-debated issue in the virus immunology for many decades. What is the probable immune mechanism & does it indeed exist? What is the evidence for & against this hypothesis? 1/
It is hypothesized that a respiratory virus infection confers immunity against the same and other respiratory viruses for a short time, perhaps a few weeks. This immunologic mechanism, known as #heterosubtypic ‘temporary non-specific immunity’ 2/
This immune protection is associated with activation of the innate immune response to viral infection mediated by the release of Type I #interferons (IFN) & other cytokines that have broad protective effects against a range of viruses 3/
Besides, viruses are known to interfere with the circulation of other viruses. For example, there is evidence that the circulation of #Rhinovirus in the community interferes & decreases the spread of seasonal & pandemic #influenza viruses 4/
Now, a recent study by the @YaleMed have reignited this debate. The researchers find that exposure to the #rhinovirus, the most frequent cause of the common cold, can protect against infection by the #SARSCoV2 virus @Yale@VirusesImmunity 6/
The study demonstrates that prior infection with a #rhinovirus protects against the replication of SARSCoV2 as a result of the intact antiviral response that was already present at the time of the infection by SARS-CoV-2 7/ pubmed.ncbi.nlm.nih.gov/34128960/
#SARSCoV2#RNA increases exponentially, with a doubling time of ∼6 h, and infection induces a robust ISG response in organoids by day 4 after infection 8/
the researchers infected airway epithelial organoid cultures with human rhinovirus and evaluated the effect that this virus had on the expression of #ACE2. Following the rhinovirus infection, the truncated form of ACE2 known as dACE2 was found to increase significantly 9/
In a 2nd study, they infected the same type of organoid cultures with #SARSCoV2, w/ or w/out a prior infection by the #rhinovirus. Three days after the initial infection, rhinovirus-infected cells were found to induce the expression of #ISGs 10/
Comparatively, SARS-CoV-2 infected organoids that were not previously exposed to rhinovirus experienced a dramatic increase in their viral load 11/
Furthermore, SARS-CoV-2 infected organoid cultures that were previously infected with rhinovirus exhibited a significant increase in IFN1 levels as compared to organoid cultures that were not previously infected with the rhinovirus 12/
At early parts in the infection, pre infected cultures were found to exhibit a greater expression of ISGs as compared to organoids that were not previously infected with the rhinovirus 13/
They found that at the start of infection with #SARSCoV2, the viral #RNA replicates at an exponential rate that induces #ISG expression levels....... 14/
......When previously infected by the #rhinovirus, the induction of #ISG expression is much more rapid, thereby allowing the innate immune system to inhibit SARSCoV2 replication more quickly 15/
Overall, the studies performed by them demonstrate that prior infection with a #rhinovirus protects against the replication of #SARSCoV2 as a result of the intact antiviral response that was already present at the time of the infection by SARS-CoV-2 16/
This graphic summarizes the key messages. Heterologous innate immunity creates a subset of individuals refractory to infection during periods of high respiratory virus circulation....... 17/
A. Virus 1 induces mucosal #IFN, which creates a refractory period following infection during which ISGs are elevated & the host is protected from a 2nd viral infection (red shading). After ISGs return to baseline, the host is again susceptible & can be infected with virus 2
18/
(B) During periods of high resp virus circulation, a fraction of the population is refractory to infection at any given time due to ISG activation from a recent infection (red shaded figures) 19/
Thus, heterologous innate immune protection could mitigate against viral transmission at times of high respiratory virus circulation 20/
There are hidden interactions between viruses that we don’t quite understand, and the above findings are a piece of the puzzle we are just now looking at! @Yale@YaleMed@florian_krammer@trvrb@profvrr 21/end
‘#Spike protein’ is the major target of #NAbs in infected/vaccinated people. The prefusion conformation of the Spike represents the most relevant target because Abs can successfully interfere w/ infection only if they prevent binding to target cells or prevent fusion itself 1/
Various approaches are adopted to express ‘#Spike’ protein in vivo, such as nucleic acid structures & virus vectors. Alternatively, other vaccine platforms like recombinant protein particles & inactivated vaccines can directly deliver this protein 2/
Most structural studies of the wild-type spike protein exhibited one #RBD in the 'open' conformation. By contrast, 2 or 3 RBDs were observed in the open conformation in the more infective #D614G mutant--the RBD #conformation plays a vital role in the infectivity of SARSCoV2 3/
Developing an #mRNA vaccine is a sure-shot way to success? No! Despite the spectacular performance of #Pfizer & #Moderna vaccines, we also have a #CureVac fiasco. We need to dig in much deeper into the intricacies of developing a highly efficacious mRNA vaccine 1/
There is more than low dose & impact of VOCs behind #CureVac’s failure. And here we once again need to salute the sheer brilliance of @kkariko . Will do a little thread to explain, why! 2/
No doubt, the #CureVac used a much lower #RNA dose. Dose is lower (12 (CureVac) vs 30 (#Pfizer) vs 100 ug (#Moderna)) but no idea how that translates to protein. Need to know how much of a role the lower dose played in the lower efficacy 3/
In the #US & #Mexico trial of #Novavax vaccine (where 50% were #Alfa variant), it shows an overall efficacy of 90.4% & 100% efficacy against moderate or severe disease, on par with the vaccines made by Pfizer-BioNTech and Moderna nytimes.com/2021/06/14/hea…
“Novavax may be used as a booster in the U.S., but it’s certainly will be the first vaccine a lot of people are going to see around the world”
#Novavax new booster vax against #Beta variant is also found highly immunogenic in #baboon studies. A strong anamnestic response was demonstrated in baboons boosted with rS-B.1.351 approximately one year after immunization with #NVXCoV2373 (rS-WU1)
#DELTA DIARY: It is clear we are now dealing with a virus that spreads far more easily - probably more than twice as easily - as the version that emerged in #Wuhan at the end of 2019 1/
The #Ro was around 2.5 when the pandemic started in Wuhan and could be as high as 8.0 for the Delta variant 2/
DELTA is evolving: A new, more genetically diverse cluster, lineage AY.1 (which is termed as #Delta+) with a new spike substitution #N417K having immune escape property, has emerged independently in some countries @vinodscaria 3/
After almost 6 months of global rollout of #Covid19 vaccines, we have some data to assess their comparative efficacy/effectiveness. There seems to be a gradient in their performances:
*Best performing: BNT162b2 (Israel, US & UK) & Moderna’s mRNA & Sputnik-V (Bahrain) 1/
But on safety front, the #inactivated vaccines have scored over all others, both on reactogenicity front & as far as rare, serious AEFIs are concerned 3/
What does #HerdImmunity mean in context with #SARSCoV2?
We don’t need the entire population to be vaccinated or the vaccines to be 100% effective (they never are); we just need them to reduce infection rates enough to get us <1. That is herd immunity 1/
The issue is more complex. Despite achieving high seropositivity in certain regions, resurgences have occurred. And in certain regions/countries, the virus suddenly retracted even in the absence of a significant sero-positivity 2/
It is not a pure mathematics. There is an interplay of infection or vaccine-induced immunity & the evolution in the virus. The 'Ro' is not a fixed number--keep on changing with the virus transmissibility. With this changes the thresholds to achieve 3/